Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy : CTS5

M. Dowsett
I. Sestak
M.M. Regan
A. Dodson
G. Viale
B. Thurlimann
M. Colleoni
J. Cuzick

January 2018

Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing women with...

OPEN Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

Molly E Klein
David J Dabbs
Yongli Shuai
Adam M Brufsky
Rachel Jankowitz
Shannon L Puhalla
Rohit Bhargava

September 2016

Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen rece...

The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer

Saad Abdalla Al-Zawi, Abdalla

September 2021

Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-positive, human e...

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.

Buus, R
Sestak, I
Kronenwett, R
Denkert, C
Dubsky, P
Krappmann, K
Scheer, M
Petry, C
Cuzick, J
Dowsett, M

November 2016

Background Estimating distant recurrence (DR) risk among women with estrogen receptor-positive (ER+)...

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

SESTAK, IVANA
CUZICK, J
Martín, M
Dubsky, P
Kronenwett, R
Rojo, F
Filipits, M
Ruiz, A
Gradishar, W
Soliman, H
Schwartzberg, L
Buus, R
Hlauschek, D
Rodríguez-Lescure, A
Gnant, M

April 2019

PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemot...

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak, I
Martín, M
Dubsky, P
Kronenwett, R
Rojo, F
Cuzick, J
Filipits, M
Ruiz, A
Gradishar, W
Soliman, H
Schwartzberg, L
Buus, R
Hlauschek, D
Rodríguez-Lescure, A
Gnant, M

July 2019

Purpose EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemothe...

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Penault-Llorca, Frédérique
Filleron, Thomas
Asselain, Bernard
Baehner, Frederick
Fumoleau, Pierre
Lacroix-Triki, Magali
Anderson, Joseph
Yoshizawa, Carl
Cherbavaz, Diana
Shak, Steven
Roca, Lise
Sagan, Christine
Lemonnier, Jérôme
Martin, Anne-Laure
Roché, Henri, H.

December 2018

International audienceThe 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy ben...

Comparison of EndoPredict and oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One 2013

Zsuzsanna Varga
Peter Sinn
Florian Fritzsche
Arthur Von Hochstetter
Aurelia Noske
Peter Schraml
Christoph Tausch
Andreas Trojan
Holger Moch

August 2016

Aim: Several multigene expression-based tests offering prognostic and predictive information in horm...

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.

Zsuzsanna Varga
Peter Sinn
Florian Fritzsche
Arthur von Hochstetter
Aurelia Noske
Peter Schraml
Christoph Tausch
Andreas Trojan
Holger Moch

AIM: Several multigene expression-based tests offering prognostic and predictive information in horm...

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

Sestak, I
Cuzick, J
Dowsett, M
Lopez-Knowles, E
Filipits, M
Dubsky, P
Cowens, JW
Ferree, S
Schaper, C
Fesl, C
Gnant, M

March 2016

Breakthrough Breast Cancer, National Institute for Health Research Biomedical Research Centre at ...

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.

Dodson, A
Okonji, D
Assersohn, L
Rigg, A
Sheri, A
Turner, N
Smith, I
Parton, M
Dowsett, M

February 2018

Purpose Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chem...

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

백순명

January 2017

Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node...

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.

Pece, S
Sestak, I
Montani, F
Tillhon, M
Maisonneuve, P
Freddi, S
Chu, K
Colleoni, M
Veronesi, P
Disalvatore, D
Viale, G
Buus, R
Cuzick, J
Dowsett, M
Di Fiore, PP

September 2022

OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist ther...

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.

Martin, Miguel
Brase, Jan C
Ruiz, Amparo
Prat, Aleix
Kronenwett, Ralf
Calvo, Lourdes
Petry, Christoph
Bernard, Philip S
Ruiz-Borrego, Manuel
Weber, Karsten E
Rodriguez, César A
Alvarez, Isabel M
Segui, Miguel A
Perou, Charles M
Casas, Maribel
Carrasco, Eva
Caballero, Rosalía
Rodriguez-Lescure, Alvaro

February 2016

There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data...

Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: A secondary analysis of the TAILORx randomized clinical trial

Sparano, Joseph A
Gray, Robert J
Makower, Della F
Albain, Kathy S
Saphner, Thomas J
Badve, Sunil S
Wagner, Lynne I
Kaklamani, Virginia G
Keane, Maccon M
Gomez, Henry L
Reddy, Pavan S
Goggins, Timothy F
Mayer, Ingrid A
Toppmeyer, Deborah L
Brufsky, Adam M
Goetz, Matthew P
Berenberg, Jeffrey L
Mahalcioiu, Catalin
Desbiens, Christine
Hayes, Daniel F
Dees, Elizabeth C
Geyer, Charles E
Olson, John A
Wood, William C
Lively, Tracy
Paik, Soonmyung
Ellis, Matthew J
Abrams, Jeffrey
Sledge, George W

March 2020

Importance: A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant re...

Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy : CTS5

M. Dowsett
I. Sestak
M.M. Regan
A. Dodson
G. Viale
B. Thurlimann
M. Colleoni
J. Cuzick

January 2018

Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing women with...

OPEN Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

Molly E Klein
David J Dabbs
Yongli Shuai
Adam M Brufsky
Rachel Jankowitz
Shannon L Puhalla
Rohit Bhargava

September 2016

Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen rece...

The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer

Saad Abdalla Al-Zawi, Abdalla

September 2021

Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-positive, human e...

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.

Buus, R
Sestak, I
Kronenwett, R
Denkert, C
Dubsky, P
Krappmann, K
Scheer, M
Petry, C
Cuzick, J
Dowsett, M

November 2016

Background Estimating distant recurrence (DR) risk among women with estrogen receptor-positive (ER+)...

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

SESTAK, IVANA
CUZICK, J
Martín, M
Dubsky, P
Kronenwett, R
Rojo, F
Filipits, M
Ruiz, A
Gradishar, W
Soliman, H
Schwartzberg, L
Buus, R
Hlauschek, D
Rodríguez-Lescure, A
Gnant, M

April 2019

PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemot...

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak, I
Martín, M
Dubsky, P
Kronenwett, R
Rojo, F
Cuzick, J
Filipits, M
Ruiz, A
Gradishar, W
Soliman, H
Schwartzberg, L
Buus, R
Hlauschek, D
Rodríguez-Lescure, A
Gnant, M

July 2019

Purpose EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemothe...

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

Penault-Llorca, Frédérique
Filleron, Thomas
Asselain, Bernard
Baehner, Frederick
Fumoleau, Pierre
Lacroix-Triki, Magali
Anderson, Joseph
Yoshizawa, Carl
Cherbavaz, Diana
Shak, Steven
Roca, Lise
Sagan, Christine
Lemonnier, Jérôme
Martin, Anne-Laure
Roché, Henri, H.

December 2018

International audienceThe 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy ben...

Comparison of EndoPredict and oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One 2013

Zsuzsanna Varga
Peter Sinn
Florian Fritzsche
Arthur Von Hochstetter
Aurelia Noske
Peter Schraml
Christoph Tausch
Andreas Trojan
Holger Moch

August 2016

Aim: Several multigene expression-based tests offering prognostic and predictive information in horm...

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.

Zsuzsanna Varga
Peter Sinn
Florian Fritzsche
Arthur von Hochstetter
Aurelia Noske
Peter Schraml
Christoph Tausch
Andreas Trojan
Holger Moch

AIM: Several multigene expression-based tests offering prognostic and predictive information in horm...

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

Sestak, I
Cuzick, J
Dowsett, M
Lopez-Knowles, E
Filipits, M
Dubsky, P
Cowens, JW
Ferree, S
Schaper, C
Fesl, C
Gnant, M

March 2016

Breakthrough Breast Cancer, National Institute for Health Research Biomedical Research Centre at ...

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.

Dodson, A
Okonji, D
Assersohn, L
Rigg, A
Sheri, A
Turner, N
Smith, I
Parton, M
Dowsett, M

February 2018

Purpose Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chem...

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

백순명

January 2017

Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node...

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.

Pece, S
Sestak, I
Montani, F
Tillhon, M
Maisonneuve, P
Freddi, S
Chu, K
Colleoni, M
Veronesi, P
Disalvatore, D
Viale, G
Buus, R
Cuzick, J
Dowsett, M
Di Fiore, PP

September 2022

OBJECTIVE: Molecular tests predicting the risk of distant recurrence (DR) can be used to assist ther...

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.

Martin, Miguel
Brase, Jan C
Ruiz, Amparo
Prat, Aleix
Kronenwett, Ralf
Calvo, Lourdes
Petry, Christoph
Bernard, Philip S
Ruiz-Borrego, Manuel
Weber, Karsten E
Rodriguez, César A
Alvarez, Isabel M
Segui, Miguel A
Perou, Charles M
Casas, Maribel
Carrasco, Eva
Caballero, Rosalía
Rodriguez-Lescure, Alvaro

February 2016

There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data...

Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: A secondary analysis of the TAILORx randomized clinical trial

Sparano, Joseph A
Gray, Robert J
Makower, Della F
Albain, Kathy S
Saphner, Thomas J
Badve, Sunil S
Wagner, Lynne I
Kaklamani, Virginia G
Keane, Maccon M
Gomez, Henry L
Reddy, Pavan S
Goggins, Timothy F
Mayer, Ingrid A
Toppmeyer, Deborah L
Brufsky, Adam M
Goetz, Matthew P
Berenberg, Jeffrey L
Mahalcioiu, Catalin
Desbiens, Christine
Hayes, Daniel F
Dees, Elizabeth C
Geyer, Charles E
Olson, John A
Wood, William C
Lively, Tracy
Paik, Soonmyung
Ellis, Matthew J
Abrams, Jeffrey
Sledge, George W

March 2020

Importance: A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant re...

Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy : CTS5

M. Dowsett
I. Sestak
M.M. Regan
A. Dodson
G. Viale
B. Thurlimann
M. Colleoni
J. Cuzick

January 2018

Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing women with...

OPEN Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

Molly E Klein
David J Dabbs
Yongli Shuai
Adam M Brufsky
Rachel Jankowitz
Shannon L Puhalla
Rohit Bhargava

September 2016

Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen rece...

The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer

Saad Abdalla Al-Zawi, Abdalla

September 2021

Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-positive, human e...

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

Abstract

Extracted data

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

Abstract

Extracted data

Related items

Related items